SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01400191

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1 (OCT1) in Healthy Volunteers

The aim of the study is to evaluate the pharmacodynamic impact of metformin in healthy Caucasian volunteers with and without single polymorphisms M420del or R61C in OCT1, thus the study hypothesis is that metformin only affect the hepatic gluconeogenesis in healthy volunteers with functional OCT1-transporters.

NCT01400191 Pharmacogenetics of Metformin

1 Interventions

Name: Metformin

Description: The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.

Type: Drug

Homozygote wildtype OCT1 Heterozygote OCT1 Homozygote OCT1 variant


Primary Outcomes

Measure: Endogenous glucose production

Time: 48 hours

Purpose: Health Services Research

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 R61C

The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1 The aim of the study is to evaluate the pharmacodynamic impact of metformin in healthy Caucasian volunteers with and without single polymorphisms M420del or R61C in OCT1, thus the study hypothesis is that metformin only affect the hepatic gluconeogenesis in healthy volunteers with functional OCT1-transporters. --- R61C ---

Inclusion Criteria: - Healthy volunteers - Written consent - Genotyped in OCT1 for (M420del and R61C) Exclusion Criteria: - Daily medication - Alcohol abuse - Pregnancy - Breastfeeding Inclusion Criteria: - Healthy volunteers - Written consent - Genotyped in OCT1 for (M420del and R61C) Exclusion Criteria: - Daily medication - Alcohol abuse - Pregnancy - Breastfeeding Pharmacogenetics of Metformin null --- R61C ---

Inclusion Criteria: - Healthy volunteers - Written consent - Genotyped in OCT1 for (M420del and R61C) Exclusion Criteria: - Daily medication - Alcohol abuse - Pregnancy - Breastfeeding Inclusion Criteria: - Healthy volunteers - Written consent - Genotyped in OCT1 for (M420del and R61C) Exclusion Criteria: - Daily medication - Alcohol abuse - Pregnancy - Breastfeeding Pharmacogenetics of Metformin null --- R61C --- --- R61C ---



HPO Nodes